Greenwich LifeSciences (NASDAQ: GLSI) has added five new clinical sites at City of Hope in Los Angeles, Orange County, Arizona, Atlanta, and Illinois to its Phase III FLAMINGO‑01 trial. The expansion brings the total number of U.S. sites to 165 and increases the worldwide network to roughly 190–200 locations.
The addition of City of Hope sites is expected to accelerate patient enrollment and broaden geographic coverage, potentially shortening the time required to reach the trial’s primary endpoint. For a company whose valuation is tightly linked to the success of FLAMINGO‑01, faster enrollment can reduce trial duration and lower the risk of costly delays—an important consideration given GLSI’s limited cash runway.
Management noted that the new sites strengthen the study’s footprint in regions where enrollment had previously been limited, thereby improving the likelihood of timely data collection and regulatory submission. The company’s leadership views the expansion as a key step toward meeting its enrollment targets and advancing toward a regulatory filing.
GLSI has no revenue and has reported consistent net losses, with a trailing EPS of –$1.46 and a Q3 2025 EPS of –$0.30 that met analyst estimates. Cash on hand was approximately $12.5 million as of January 23 2026, underscoring the urgency of completing the trial efficiently. The City of Hope expansion is therefore a strategic move to mitigate financial risk by potentially shortening the trial timeline and reducing ongoing operating expenses.
Investors have been closely monitoring trial progress; the expansion is viewed positively as it may accelerate enrollment and reduce the risk of delays, thereby supporting the company’s path to regulatory approval and eventual commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.